Dr. Reddys Laboratories Ltd.

In the process of acquiring 100% stake in Netherlands-based specialty pharmaceutical company OctoPlus NV, Dr Reddy’s Laboratories has, so far, acquired 79.4% stake of Octoplus. Of the aforementioned stake, the company has bought 15.9% shares (83,59,858 shares) through open market and 63.5% shares (3,34,48,839 shares) were committed by certain members of the OctoPlus Board and other shareholders though irrevocable undertaking.

The entire acquisition is expected to be completed by the end of the current financial year. As per the agreement, Dr Reddy’s made an open offer to purchase all outstanding shares of OctoPlus at an offer price of 0.52 euro in cash for each share.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.